The term cardiometabolic disease encompasses a range of lifestyle-related conditions, including Metabolic syndrome (MetS) and type 2 diabetes (T2D), that are characterized by different combinations of cardiovascular (CV) risk factors, including dyslipidemia, abdominal obesity, hypertension, hyperglycemia/insulin resistance, and vascular inflammation. These risk factors individually and interdependently increase the risk of CV and cerebrovascular events, and represent one of the biggest health challenges worldwide today. CV diseases account for almost 50% of all deaths in Europe and around 30% of all deaths worldwide. Furthermore, the risk of CV death is increased twofold to fourfold in people with T2D. Whilst the clinical management of CV d...
Statins are used widely for the treatment of cardiovascular (CV) disease because they improve the li...
Abstract Background The diabetogenic action of sta...
There is no doubt nowadays that statins exert a diabetogenic action. The evidence comes from observa...
Managing dyslipidaemia is central to the management of cardiovascular disease. Statins are the corne...
The US Food and Drink Administration (FDA) recently published a warning that statin usage may increa...
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, whi...
Statins are potent hypolipidemic drugs effectively reducing low-density lipoprotein (LDL) cholestero...
Statins are one of the most widely used drug classes, with approximately 50 million prescriptions di...
Background: As the clinical complexity of patients at high cardiovascular risk and with multiple com...
Altres ajuts: Laboratorios del Dr. Esteve, S.A.U. has supported the scientific committee to undertak...
Background: Type 2 diabetics are at high risk of atherosclerosis and cardiovascular (CV) events due ...
. The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in pa...
Introduction: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are wid...
Pitavastatin is the newest member of the HMG-CoA reductase inhibitor family and is approved as adjun...
The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in pati...
Statins are used widely for the treatment of cardiovascular (CV) disease because they improve the li...
Abstract Background The diabetogenic action of sta...
There is no doubt nowadays that statins exert a diabetogenic action. The evidence comes from observa...
Managing dyslipidaemia is central to the management of cardiovascular disease. Statins are the corne...
The US Food and Drink Administration (FDA) recently published a warning that statin usage may increa...
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, whi...
Statins are potent hypolipidemic drugs effectively reducing low-density lipoprotein (LDL) cholestero...
Statins are one of the most widely used drug classes, with approximately 50 million prescriptions di...
Background: As the clinical complexity of patients at high cardiovascular risk and with multiple com...
Altres ajuts: Laboratorios del Dr. Esteve, S.A.U. has supported the scientific committee to undertak...
Background: Type 2 diabetics are at high risk of atherosclerosis and cardiovascular (CV) events due ...
. The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in pa...
Introduction: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are wid...
Pitavastatin is the newest member of the HMG-CoA reductase inhibitor family and is approved as adjun...
The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in pati...
Statins are used widely for the treatment of cardiovascular (CV) disease because they improve the li...
Abstract Background The diabetogenic action of sta...
There is no doubt nowadays that statins exert a diabetogenic action. The evidence comes from observa...